{"downloaded": true, "htmlmade": false, "full": {"id": "30596402", "source": "MED", "pmid": "30596402", "pmcid": "PMC6314205", "fullTextIdList": {"fullTextId": "PMC6314205"}, "doi": "10.1111/bjh.15585", "title": "Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.", "authorString": "Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Langerak A, Roden JE, Press OW, Gopal AK.", "authorList": {"author": [{"fullName": "Budde LE", "firstName": "Lihua E", "lastName": "Budde", "initials": "LE", "authorId": {"@type": "ORCID", "#text": "0000-0003-1464-5494"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA."}}}, {"fullName": "Wu D", "firstName": "David", "lastName": "Wu", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Laboratory Medicine, University of Washington, Seattle, WA, USA."}}}, {"fullName": "Martin DB", "firstName": "Daniel B", "lastName": "Martin", "initials": "DB", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA."}}}, {"fullName": "Philip M", "firstName": "Mary", "lastName": "Philip", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA."}}}, {"fullName": "Shustov AR", "firstName": "Andrei R", "lastName": "Shustov", "initials": "AR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA."}}}, {"fullName": "Smith SD", "firstName": "Stephen D", "lastName": "Smith", "initials": "SD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA."}}}, {"fullName": "Gooley TA", "firstName": "Ted A", "lastName": "Gooley", "initials": "TA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA."}}}, {"fullName": "Chen TL", "firstName": "Tara L", "lastName": "Chen", "initials": "TL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA."}}}, {"fullName": "Libby EN", "firstName": "Edward N", "lastName": "Libby", "initials": "EN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA."}}}, {"fullName": "Chen EY", "firstName": "Eric Y", "lastName": "Chen", "initials": "EY", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Group Health Permanente, Seattle, WA, USA."}}}, {"fullName": "Kojouri K", "firstName": "Kiarash", "lastName": "Kojouri", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Skagit Valley Hospital Regional Center, Mount Vernon, WA, USA."}}}, {"fullName": "Langerak A", "firstName": "Alan", "lastName": "Langerak", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "St. Alphonsus Regional Medical Center, Boise, ID, USA."}}}, {"fullName": "Roden JE", "firstName": "Jennifer E", "lastName": "Roden", "initials": "JE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA."}}}, {"fullName": "Press OW", "firstName": "Oliver W", "lastName": "Press", "initials": "OW", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA."}}}, {"fullName": "Gopal AK", "firstName": "Ajay K", "lastName": "Gopal", "initials": "AK", "authorId": {"@type": "ORCID", "#text": "0000-0003-3023-6834"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA."}, {"affiliation": "Department of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0003-1464-5494"}, {"@type": "ORCID", "#text": "0000-0003-3023-6834"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "4", "volume": "183", "journalIssueId": "2753305", "dateOfPublication": "2018 Nov", "monthOfPublication": "11", "yearOfPublication": "2018", "printPublicationDate": "2018-11-01", "journal": {"title": "British journal of haematology", "ISOAbbreviation": "Br J Haematol", "medlineAbbreviation": "Br J Haematol", "NLMid": "0372544", "ISSN": "0007-1048", "ESSN": "1365-2141"}}, "pubYear": "2018", "pageInfo": "601-607", "abstractText": "We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/II study for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and classic Hodgkin lymphoma (HL). Therapy consisted of 60-120\u00a0mg/m<sup>2</sup> per day bendamustine on days 1 and 2 in combination with carboplatin, etoposide and rituximab (only for CD20<sup>+</sup> lymphoma) used in the (R)ICE regimen for up to 2 cycles. The objectives were to define a maximally tolerated dose (MTD) of bendamustine, determine safety and toxicity, assess efficacy, and evaluate impact on stem cell collection. Forty-eight patients were treated of which 71% had refractory disease. No dose-limiting toxicities were observed. The recommended phase II dose of bendamustine was 120\u00a0mg/m<sup>2</sup> per day on days 1 and 2. Response rates were 85% (70% complete response, CR) in HL, and 65% (40% CR) in DLBCL. Stem cell collection was successful in 30 of 32 patients. The most common non-haematological toxicities \u2265grade 3 were febrile neutropenia (8%) and dehydration (8%). The T(R)EC regimen safely yields high response rates, successfully mobilizes peripheral blood stem cells and compares favourably to RICE, offering an effective outpatient treatment option for patients with relapsed or refractory DLBCL and HL.", "affiliation": "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "K24 CA184039", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P01 CA044991", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Dehydration", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "EP", "qualifierName": "epidemiology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Carboplatin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Etoposide", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Prospective Studies"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, Large B-Cell, Diffuse", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "EP", "qualifierName": "epidemiology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Febrile Neutropenia", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "EP", "qualifierName": "epidemiology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Bendamustine Hydrochloride", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Rituximab", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}]}, "keywordList": {"keyword": ["Lymphoma", "Clinical Trial", "Bendamustine", "Stem Cell Mobilization", "Trec", "Salvage Regimen"]}, "chemicalList": {"chemical": [{"name": "Carboplatin", "registryNumber": "BG3F62OND5"}, {"name": "Etoposide", "registryNumber": "6PLQ3CP4P3"}, {"name": "Bendamustine Hydrochloride", "registryNumber": "981Y8SX18M"}, {"name": "Rituximab", "registryNumber": "4F4X42SYQ6"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15585"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6314205"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6314205?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15585"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "2", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS986659", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-07-15", "dateOfCreation": "2019-01-01", "firstIndexDate": "2019-01-01", "fullTextReceivedDate": "2020-10-26", "dateOfRevision": "2020-03-09", "electronicPublicationDate": "2018-09-14", "firstPublicationDate": "2018-09-14", "embargoDate": "2019-11-01"}, "abstract": "We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/II study for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and classic Hodgkin lymphoma (HL). Therapy consisted of 60-120\u00a0mg/m<sup>2</sup> per day bendamustine on days 1 and 2 in combination with carboplatin, etoposide and rituximab (only for CD20<sup>+</sup> lymphoma) used in the (R)ICE regimen for up to 2 cycles. The objectives were to define a maximally tolerated dose (MTD) of bendamustine, determine safety and toxicity, assess efficacy, and evaluate impact on stem cell collection. Forty-eight patients were treated of which 71% had refractory disease. No dose-limiting toxicities were observed. The recommended phase II dose of bendamustine was 120\u00a0mg/m<sup>2</sup> per day on days 1 and 2. Response rates were 85% (70% complete response, CR) in HL, and 65% (40% CR) in DLBCL. Stem cell collection was successful in 30 of 32 patients. The most common non-haematological toxicities \u2265grade 3 were febrile neutropenia (8%) and dehydration (8%). The T(R)EC regimen safely yields high response rates, successfully mobilizes peripheral blood stem cells and compares favourably to RICE, offering an effective outpatient treatment option for patients with relapsed or refractory DLBCL and HL.", "Keywords": ["Lymphoma", "Clinical Trial", "Bendamustine", "Stem Cell Mobilization", "Trec", "Salvage Regimen"], "journaltitle": "British journal of haematology", "authorinfo": ["Budde LE", "Wu D", "Martin DB", "Philip M", "Shustov AR", "Smith SD", "Gooley TA", "Chen TL", "Libby EN", "Chen EY", "Kojouri K", "Langerak A", "Roden JE", "Press OW", "Gopal AK"], "title": "Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial."}